→ Vertex CFO Thomas Graney has abruptly resigned. The bellwether Boston biotech says that COO Ian Smith will fill in on a temporary basis. There was no explanation for the departure — Graney handed in his resignation letter on December 13 — outlined in an SEC filing Monday morning. UPDATE: After we reported this Monday, a startup named Generation Bio — helmed by Geoff McDonough — put out a notice that Graney had decided to jump over to become their CFO. So mystery solved.
→ Eli Lilly $LLY is boasting about a big win in a head-to-head study pitting their drug Taltz against AbbVie’s $ABBV powerhouse drug Humira. Researchers say their drug beat out the world’s top selling drug on the primary — the proportion of patients simultaneously achieving at least a 50% reduction in disease activity…as well as complete skin clearance — and all major secondary endpoints. Lilly recruited 566 active PsA patients for the Phase IIIb study.
→ Daiichi Sankyo has out-licensed its Phase I ROS1/NTRK inhibitor DS-6051 to Basking Ridge, NJ-based AnHeart Therapeutics for an unspecified upfront and milestones. The two companies will complete two ongoing Phase I studies, after which AnHeart will be in control.
→ The promise of RNA splicing is enticing high-profile names. Eisai’s US unit, H3 Biomedicine, and Bristol-Myers Squibb $BMY are joining hands to see whether therapeutics leveraging H3’s RNA splicing platform can provide a more powerful response against cancer. The deal comes months after antisense startup Stoke Therapeutics — whose experimental drug is designed to up-regulate production of a protein missing in patients with Dravet syndrome by targeting RNA splicing — raked in $90 million in a Series B round.
→ London’s White City hub has attracted another life sciences player — GammaDelta Therapeutics — to the party. The West London region, which borders Imperial College London’s research and innovation campus, has become a British biotech favorite, most recently luring Novartis $NVS to set up shop in the WestWorks, part of the rebirth of the old BBC Media Village campus in the area . GammaDelta has also relocated to WestWorks from the London BioScience Innovation Centre near St Pancras.
→ Shanghai Henlius Biotech, the Fosun/Henlius joint venture that was once tipped to be the first company to take advantage of Hong Kong’s new listing rules for pre-revenue biotechs, has applied for an IPO at the HKEX. Its pipeline is divided between biosimilars and novel biologics targeting cancer and other diseases.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription